Simvastatin
- Generic Name
- Simvastatin
- Brand Names
- Cholib, FloLipid, Simcor, Vytorin, Zocor
- Drug Type
- Small Molecule
- Chemical Formula
- C25H38O5
- CAS Number
- 79902-63-9
- Unique Ingredient Identifier
- AGG2FN16EV
- Background
Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of Aspergillus terreus. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liv...
- Indication
Simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).
...
- Associated Conditions
- Cardiovascular Events, Diabetes Mellitus, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Mixed Hyperlipidemia, History of coronary heart disease cardiovascular event, History of stroke or other cerebrovascular disease cardiovascular event
- Associated Therapies
- -
Pharmacodynamic Drug Interaction Between Cilostazol and Statins
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 63
- Registration Number
- NCT01870466
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Simvastatin in Healthy Volunteers
- First Posted Date
- 2013-03-29
- Last Posted Date
- 2013-03-29
- Target Recruit Count
- 22
- Registration Number
- NCT01821027
Efficacy Study of SIMVASTATIN to Treat Chronic Rhinosinusitis After Failure of Optimal Treatment
- First Posted Date
- 2013-01-18
- Last Posted Date
- 2015-07-13
- Target Recruit Count
- 7
- Registration Number
- NCT01771198
- Locations
- 🇨🇦
Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada
Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins
- Conditions
- Interventions
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 12
- Registration Number
- NCT01764451
- Locations
- 🇺🇸
University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2067
- Registration Number
- NCT01763866
- Locations
- 🇬🇧
Research Site, Whitby, United Kingdom
Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib
- Conditions
- Interventions
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT01725230
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2016-12-19
- Lead Sponsor
- UCSF Benioff Children's Hospital Oakland
- Target Recruit Count
- 24
- Registration Number
- NCT01702246
- Locations
- 🇺🇸
Children's Hospital and Research Center Oakland, Oakland, California, United States
A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT01689623
The Effect of XueZhiKang on Fatigue：Comparing With Simvastatin
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Wenzhou Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT01686451
- Locations
- 🇨🇳
Second Hispital of Wenzhou Medical University, Wenzhou, Zhejiang, China
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 299
- Registration Number
- NCT01678820
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.